Krazati (adagrasib tablets - Mirati Therapeutics) — Cigna

Initial criteria

• Patient is age ≥ 18 years
• Patient has metastatic disease
• Patient has KRAS G12C mutation-positive disease
• The medication will be used as subsequent therapy

Approval duration

1 year